Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies

F Gatto, M Arvigo, D Ferone - Journal of Endocrinological Investigation, 2020 - Springer
Abstract Background Somatostatin receptors (SSTs) are widely co-expressed in pituitary
tumors. SST 2 and SST 5 are the most represented SST subtypes. First-generation …

A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells

MC Vázquez-Borrego, MA Gálvez-Moreno… - …, 2020 - karger.com
Background: Pituitary neuroendocrine tumors (PitNETs) represent approximately 15% of all
intracranial tumors and usually are associated with severe comorbidities. Unfortunately, a …

Diagnosing thyrotropin-secreting pituitary adenomas by short-term somatostatin analogue test

R Han, L Shen, J Zhang, J Xie, W Fang, Q Sun, L Bian… - Thyroid, 2020 - liebertpub.com
Background: Diagnosis of thyrotropin (TSH)-secreting pituitary adenomas (TSHoma) before
surgery remains a challenge, especially for microadenomas. We aimed to establish a short …

Somatostatin receptor profile in pituitary thyrotroph adenomas

E Thodou, G Kontogeorgos - Clinical Neurology and Neurosurgery, 2020 - Elsevier
Objectives Thyrotroph adenomas are the most infrequent adenohypophysial tumors.
Somatostatin (SST) inhibits hormone secretion and suppresses cell proliferation. SST …

Identification of drugs targeting multiple viral and human proteins using computational analysis for repurposing against COVID-19

S Kumar, P Kumari, G Agnihotri, PV Kumar, B Singh… - 2020 - researchsquare.com
The SARS-CoV2 is a highly contagious pathogen that causes COVID-19 disease. It has
affected millions of people globally with an average lethality of~ 3%. Unfortunately, there is …